Annexin Pharmaceuticals: RVO data on the horizon - Redeye
Redeye reviews the case of Annexin in the wake of the company’s Q1 report and recent newsflow. We conclude that 2023 will be an eventful year for the company, with initial phase II data in RVO potentially this summer.
ANNONS
Redeye reviews the case of Annexin in the wake of the company’s Q1 report and recent newsflow. We conclude that 2023 will be an eventful year for the company, with initial phase II data in RVO potentially this summer.